Cosentyx is a medication used to treat several autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The active ingredient in Cosentyx is secukinumab, which works by targeting a specific protein in the body that is involved in the inflammatory response.

Regarding the safety of using Cosentyx for extended periods, the available sources provide some insights. According to Drug Patent Watch [1], Cosentyx was approved by the FDA in 2015, and its patent is set to expire in 2032. This suggests that the drug has undergone rigorous testing and has been deemed safe for use by regulatory agencies.

A study published in Arthritis Research & Therapy [2] evaluated the long-term safety and efficacy of Cosentyx in treating psoriatic arthritis. The study followed patients for up to 4 years and found that the drug was generally well-tolerated, with no new safety concerns arising over time. The study also reported sustained improvements in disease activity and physical function among patients.

Another study published in PubMed [3] evaluated the safety and efficacy of Cosentyx in treating ankylosing spondylitis. The study followed patients for up to 5 years and found that the drug was generally safe and well-tolerated, with no new safety concerns arising over time. The study also reported sustained improvements in disease activity and quality of life among patients.

Overall, the available evidence suggests that Cosentyx is generally safe for extended use in treating autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, as with any medication, there may be some risks associated with long-term use, and patients should discuss the potential benefits and risks with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1882-2
[3] https://pubmed.ncbi.nlm.nih.gov/35146532/